Preliminary data demonstrate FPI-2265 is active in heavily pretreated patients with progressive metastatic castration-resistant prostate cancer (mCRPC), including those who received prior lutetium-based radioconjugates
Read more at newswire.caFusion Pharmaceuticals Announces Presentation of Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the AACR Annual Meeting 2024
Newswire.ca -
Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here